Alligator Bioscience AB - Redeye

More documents

Recommendations

Info

ADC-1015: A Bispecific Immune Activator <strong>Alligator</strong> is developing a bispecific immune activating antibody for local treatment of metastasizing cancer - ADC-1015. Ø Superior to combination of two monospecific compounds Ø Novelty – strong IP can be obtained ADC-1014 ADC-1015 Undisclosed 20 CONFIDENTIAL
World Class Key Opinion Leaders <strong>Alligator</strong> is building a network of international opinion leaders within key areas for immunotherapy of cancer. Professor Thomas Tötterman et al., Clinical Immunology, Uppsala University Professor Carl Borrebaeck et al., Immunotechnology, Lund University Professor Jeffrey Weber Immunotherapy of Cancer, Moffitt Cancer Center, US Professor Ronald Levy et al., Immunotherapy of Cancer, Stanford University, US 21
Page 1 and 2: Alligator Bioscience AB Cancer Immu
Page 3 and 4: Technology & Product Growth FIND ®
Page 5 and 6: Immunotherapy of Cancer 5 CONFIDENT
Page 7 and 8: Local Immunotherapy: Competitive Ed
Page 9 and 10: Designing ADC-1013 for Local Immuno
Page 11 and 12: 1. Systemic Anti-Tumor Effect Twin
Page 13 and 14: 2. Long Term Immunity Cured mice re
Page 15 and 16: Transgenic Mice Transgenic mice - g
Page 17 and 18: ADC-1013 Status and Development Pla
Page 19: ADC-1015: A Bispecific Immune Activ
Page 23 and 24: Financing Needs Rest of 2013 Ø Ong
Page 25: Share Capital - February 18, 2013 S

Alligator Bioscience AB - Redeye

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?